Gastro Hep Advances (Jan 2022)

Urine and Serum Metabolomic Profiles Differ by Disease Activity in Pregnant Women With Inflammatory Bowel Diseases

  • Richard Y. Wu,
  • Parul Tandon,
  • Joyce S. Oh,
  • Lindsy Ambrosio,
  • Naomi Hotte,
  • Binal Shah-Gandhi,
  • Karen L. Madsen,
  • Levinus A. Dieleman,
  • Shokrollah Elahi,
  • Karen I. Kroeker,
  • Vivian Huang

Journal volume & issue
Vol. 1, no. 6
pp. 993 – 1005

Abstract

Read online

Background and Aims: Inflammatory bowel disease (IBD), inclusive of ulcerative colitis and Crohn’s disease, are chronic inflammatory conditions that impact women of childbearing age. It has been previously shown that IBD is associated with altered metabolomic profiles, but whether metabolomic changes also affect pregnant patients with IBD is completely unknown. Methods: This was a prospective cohort study comprised of 48 pregnant women with IBD who were followed throughout preconception and pregnancy. IBD disease activity was measured using biochemical markers C-reactive protein or fecal calprotectin using enzyme-linked immunosorbent assay and clinical disease activity using Harvey-Bradshaw Index or partial Mayo scores. Serum and urine samples were collected from preconception, trimester 1, and trimester 2 and analyzed using nuclear magnetic resonance spectroscopy combined with metabolomics set enrichment analysis. Results: We identified a total of 24 urine metabolites and 17 serum metabolites which were altered by active disease across pregnancy. First trimester (T1) active disease-associated metabolites were enriched in “amino acid metabolism” and “fatty-acid β-oxidation.” The leading urine metabolites at T1 were trimethyl-N-oxide (TMAO), succinic acid, and 3-hydroxy-2-methylbutyric acid, and leading serum metabolites were TMAO, glucose, and acetic acid. Multivariate modeling using serum TMAO, glucose, and acetic acid predicts T1 disease activity and correlated with mode of delivery and infant weights at delivery. Moreover, cross–time point modeling using metabolomes predicted future disease flare-up during pregnancy. Conclusion: These results suggest select host metabolites may be able to discriminate and predict disease activity and are correlated with pregnancy outcomes at delivery. This warrants further validation of metabolomics to monitor IBD in pregnancy.

Keywords